5-HT Receptor Modulators for Therapeutic Use in the Treatment of Obsessive-Compulsive Disorder and Other Psychological Disorders.
作者信息
Kargbo Robert B
机构信息
Usona Institute, 277 Granada Drive, San Luis Obispo, California 93401-7337, United States.
出版信息
ACS Med Chem Lett. 2022 Apr 20;13(5):770-772. doi: 10.1021/acsmedchemlett.2c00153. eCollection 2022 May 12.
Abstract
摘要
相似文献
1
5-HT Receptor Modulators for Therapeutic Use in the Treatment of Obsessive-Compulsive Disorder and Other Psychological Disorders.用于治疗强迫症及其他心理障碍的5-羟色胺受体调节剂
ACS Med Chem Lett. 2022 Apr 20;13(5):770-772. doi: 10.1021/acsmedchemlett.2c00153. eCollection 2022 May 12.
2
Psychopathology and personality characteristics in relation to blood serotonin in Tourette's syndrome and obsessive-compulsive disorder.抽动秽语综合征和强迫症中与血液血清素相关的精神病理学和人格特征
J Psychopharmacol. 2001 Jun;15(2):111-9. doi: 10.1177/026988110101500208.
3
Effect of Escitalopram on Serum GDNF and BDNF Levels and 5-HT Level of Brain Tissue of Obsessive-Compulsive Disorder Rats.艾司西酞普兰对强迫症大鼠血清 GDNF 和 BDNF 水平及脑组织 5-HT 水平的影响。
Cell Mol Neurobiol. 2020 Aug;40(6):991-997. doi: 10.1007/s10571-020-00788-4. Epub 2020 Jan 11.
4
Serotonin-1D hypothesis of obsessive-compulsive disorder: an update.强迫症的5-羟色胺-1D假说：最新进展
J Clin Psychiatry. 2004;65 Suppl 14:18-21.
5
The putative catalytic role of higher serotonin bioavailability in the clinical response to exposure and response prevention in obsessive-compulsive disorder.较高的血清素生物利用度在强迫症暴露与反应阻止治疗临床反应中的假定催化作用。
Braz J Psychiatry. 2016 Oct-Dec;38(4):287-293. doi: 10.1590/1516-4446-2015-1721. Epub 2016 Oct 17.
6
The serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies.强迫症的血清素假说：药物激发试验的启示
J Clin Psychiatry. 1992 Apr;53 Suppl:17-28.
7
Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder.舒马曲坦（5-羟色胺1D受体激动剂）不会加重强迫症的症状。
Psychopharmacology (Berl). 1998 Dec;140(3):365-70. doi: 10.1007/s002130050777.
8
Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results.氯米帕明与氟西汀治疗强迫症的对照比较。行为学和生物学结果。
Arch Gen Psychiatry. 1990 Oct;47(10):926-32. doi: 10.1001/archpsyc.1990.01810220042005.
9
The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder.创伤和创伤后应激障碍对强迫症患者治疗反应的影响。
Eur Arch Psychiatry Clin Neurosci. 2010 Mar;260(2):91-9. doi: 10.1007/s00406-009-0015-3.
10
Managing obsessive compulsive disorder.强迫症的管理。
Aust Prescr. 2015 Aug;38(4):121-3. doi: 10.18773/austprescr.2015.040. Epub 2015 Aug 3.
本文引用的文献
1
Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity.致幻剂诱导神经可塑性的生化机制。
Biochemistry. 2022 Feb 1;61(3):127-136. doi: 10.1021/acs.biochem.1c00812. Epub 2022 Jan 21.
2
Beating pain with psychedelics: Matter over mind?用迷幻剂战胜疼痛：物质战胜意识？
Neurosci Biobehav Rev. 2022 Mar;134:104482. doi: 10.1016/j.neubiorev.2021.12.005. Epub 2021 Dec 16.
3
Psychedelic medicines for mood disorders: current evidence and clinical considerations.用于治疗情绪障碍的迷幻药物：当前证据与临床考量
Curr Opin Psychiatry. 2022 Jan 1;35(1):22-29. doi: 10.1097/YCO.0000000000000759.
4
Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.致幻剂治疗绝症患者的抑郁、焦虑和存在性困扰：系统评价。
Psychopharmacology (Berl). 2022 Jan;239(1):15-33. doi: 10.1007/s00213-021-06027-y. Epub 2021 Nov 23.
5
Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery.新型方法、候选药物和疼痛药物发现中的靶点。
J Med Chem. 2021 May 27;64(10):6523-6548. doi: 10.1021/acs.jmedchem.1c00028. Epub 2021 May 6.
6
Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.致幻剂在精神健康中的应用：LSD、裸盖菇素、MDMA 和氯胺酮的临床前和临床研究。
J Neurosci. 2021 Feb 3;41(5):891-900. doi: 10.1523/JNEUROSCI.1659-20.2020. Epub 2020 Nov 30.
Zotero 插件